Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE014 (NLD) (Dr. Moreau)
· consented 2023-09-07
Adverse events
6
Serious AEs
1
Open data queries
0
Luna dropout signal
–
Adverse events
mild
assessed
2026-08-18
Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-09-27 (study day 5); relationship: Y
moderate
assessed
2026-08-18
Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-10-07 (study day 15); relationship: not assessed
severe
serious
assessed
2026-08-18
Grade 3 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-11-02 (study day 41); relationship: not assessed; serious criteria: hospitalization
moderate
assessed
2026-08-18
Grade 2 Colitis — outcome: RECOVERED/RESOLVED; onset 2023-11-11 (study day 50); relationship: Y
moderate
assessed
2026-08-18
Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2024-02-13 (study day 144); relationship: not assessed
mild
assessed
2026-08-18
Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2024-05-04 (study day 225); relationship: N
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.